Coaxing HIV-1 from resting CD4 T cells
Top Cited Papers
- 1 May 2004
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (8) , 1101-1108
- https://doi.org/10.1097/00002030-200405210-00003
Abstract
Background: Histone deacetylase (HDAC), a host mediator of gene repression, inhibits HIV gene expression and virus production and may contribute to quiescence of HIV within resting CD4 T cells. Objectives: To test the ability of valproic acid (VPA), an inhibitor of HDAC in clinical use, to induce expression of HIV from resting CD4 T cells. Methods: Chromatin immunoprecipitation measured the capability of VPA to deacetylate the HIV promoter, a remodeling of chromatin linked to gene expression. The effect of VPA on resting CD4 T cell phenotype was measured by flow cytometric analysis, and its effect on de novo HIV infection of peripheral blood mononuclear cells was measured ex vivo. Outgrowth of HIV from resting CD4 T cells of aviremic, HIV-infected donors treated with highly active antiretroviral therapy was compared in limiting-dilution cultures after mitogen stimulation or exposure to VPA. Results: VPA induced acetylation at the integrated HIV proviral promoter, but CD4 cells exposed to VPA did not become activated or more permissive for de novo HIV infection. VPA induced outgrowth of HIV from the resting CD4 cells of aviremic patients at concentrations achievable in vivo as frequently as did mitogen stimulation. Conclusions: With advances in antiretroviral therapy, HIV infection might be cleared by intensive time-limited treatment coupled with practical strategies that disrupt latency without enhancing new infection. HDAC inhibitors are capable of inducing expression of quiescent provirus, without fully activating cells or enhancing de novo infection, and may be useful in future clinical protocols that seek to eradicate HIV infection.Keywords
This publication has 45 references indexed in Scilit:
- Resting CD4 + T Lymphocytes but Not Thymocytes Provide a Latent Viral Reservoir in a Simian Immunodeficiency Virus- Macaca nemestrina Model of Human Immunodeficiency Virus Type 1-Infected Patients on Highly Active Antiretroviral TherapyJournal of Virology, 2003
- Intensification and Stimulation Therapy for Human Immunodeficiency Virus Type 1 Reservoirs in Infected Persons Receiving Virally Suppressive Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2002
- Synergistic Activation of Human Immunodeficiency Virus Type 1 Promoter Activity by NF-κB and Inhibitors of Deacetylases: Potential Perspectives for the Development of Therapeutic StrategiesJournal of Virology, 2002
- Direct and Quantitative Single-Cell Analysis of Human Immunodeficiency Virus Type 1 Reactivation from LatencyJournal of Virology, 2002
- Pilot Study of the Effects of Intermittent Interleukin‐2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV InfectionThe Journal of Infectious Diseases, 2002
- Reservoirs for HIV-1: Mechanisms for Viral Persistence in the Presence of Antiviral Immune Responses and Antiretroviral TherapyAnnual Review of Immunology, 2000
- Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapyAIDS, 1999
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- Cell Type-Dependent Effect of Sodium Valproate on Human Immunodeficiency Virus Type 1 Replicationin VitroAIDS Research and Human Retroviruses, 1997
- Sodium Valproate, an Anticonvulsant Drug, Stimulates Human Immunodeficiency Virus Type 1 Replication Independently of Glutathione LevelsJournal of General Virology, 1996